"Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results." by Philip Mease

Selected Works of Philip Mease, MD

Follow Contact

Article

Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results.

Arthritis Rheumatol

Philip Mease

Link

Document Type

Article

Publication Date

2-1-2019

Disciplines

Orthopedics and
Rheumatology

Clinical Institute

Orthopedics & Sports Medicine

Specialty

Orthopedics

Specialty

Rheumatology

Citation Information

Philip Mease. "Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results." Arthritis Rheumatol (2019)
Available at: http://works.bepress.com/philip-mease/408/